Eli Lilly and Company (NYSE:LLY) Shares Purchased by XML Financial LLC

XML Financial LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,825 shares of the company’s stock after acquiring an additional 50 shares during the quarter. XML Financial LLC’s holdings in Eli Lilly and Company were worth $1,409,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in LLY. Beck Bode LLC purchased a new stake in Eli Lilly and Company in the second quarter valued at approximately $15,036,000. AQR Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 17.3% in the 2nd quarter. AQR Capital Management LLC now owns 474,552 shares of the company’s stock valued at $429,650,000 after acquiring an additional 70,122 shares during the last quarter. APG Asset Management US Inc. increased its stake in shares of Eli Lilly and Company by 0.8% in the second quarter. APG Asset Management US Inc. now owns 204,328 shares of the company’s stock worth $186,831,000 after acquiring an additional 1,586 shares during the period. APG Asset Management N.V. raised its holdings in shares of Eli Lilly and Company by 6.7% during the second quarter. APG Asset Management N.V. now owns 703,220 shares of the company’s stock worth $594,058,000 after purchasing an additional 44,133 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in Eli Lilly and Company by 0.7% during the second quarter. Ameriprise Financial Inc. now owns 3,027,901 shares of the company’s stock valued at $2,741,832,000 after purchasing an additional 22,392 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on LLY. Truist Financial lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Deutsche Bank Aktiengesellschaft decreased their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective on the stock. Citigroup boosted their target price on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research note on Friday, October 25th. Finally, Barclays cut their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,002.22.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $766.00 on Friday. The firm has a 50-day simple moving average of $776.31 and a 200-day simple moving average of $850.93. The stock has a market capitalization of $727.18 billion, a price-to-earnings ratio of 82.81, a price-to-earnings-growth ratio of 1.56 and a beta of 0.41. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 52 week low of $624.68 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period last year, the business earned $0.10 earnings per share. On average, equities analysts predict that Eli Lilly and Company will post 12.98 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a $1.50 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.78%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

Eli Lilly and Company announced that its board has authorized a stock repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.